Filing Flows › Corcept Therapeutics (CORT) › Capital expenditures
Corcept Therapeutics (CORT) capital expenditures by quarter
Corcept Therapeutics' capital expenditures were $709K in Q3 2026 (third quarter 2026), -72% from Q2 2026. Over the last 5 quarters it ranged from $50K (Q4 2025) to $2.5M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $709K | -72% | — |
| Q2 2026 | $2.5M | 51× | 44× |
| Q4 2025 | $50K | -12% | — |
| Q2 2025 | $57K | -45% | — |
| Q1 2025 | $104K | — | — |
Q3 2026 at a glance
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
What is Corcept Therapeutics' capital expenditures?
Corcept Therapeutics' capital expenditures were $709K in Q3 2026 (third quarter 2026), -72% from Q2 2026.
How has Corcept Therapeutics' capital expenditures changed?
Over the last 5 quarters it ranged from $50K (Q4 2025) to $2.5M (Q2 2026).